FRI0621 ASSOCIATIONS BETWEEN ORGAN INVOLVEMENTS AND GENDER, ALLERGY, AND MALIGNANCY IN 166 PATIENTS WITH IGG4-RELATED DISEASE
Authors: Hajime Yoshifuji, Mirei Shirakashi, Yuzo Kodama, Tsutomu Chiba, Motohisa Yamamoto, Hiroki Takahashi, Kazushige Uchida, Kazuichi Okazaki, Tetsuya Ito, Shigeyuki Kawa, Kazunori Yamada, Mitsuhiro Kawano, Shintaro Hirata, Yoshiya Tanaka, Masafumi Moriyama, Seiji Nakamura, Terumi Kamisawa, Shoko Matsui, Hiroto Tsuboi, Takayuki Sumida, Motoko Shibata, Hiroshi Goto, Yasuharu Sato, Tadashi Yoshino, Tsuneyo Mimori
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Symptomatic differences between male and female patients with IgG4-related disease (IgG4-RD) have been reported [1]. Associations between IgG4-RD and allergy and malignancy have also been reported, although they are controversial. <h3>Objectives</h3> We previously analyzed the treatment course of IgG4-RD using a multi-center cohort [2]. In the present study, we investigated the associations between organ symptoms and gender, allergic diseases, and malignancies. <h3>Methods</h3> Data of 166 patients with a definitive diagnosis of IgG4-RD were retrospectively analyzed. <h3>Results</h3> The cohort consisted of 108 men (65%) and 58 women (35%). Most frequently, the submandibular gland (52%), pancreas (46%), lachrymal gland (43%), and lymph node (38%) were affected. Furthermore, we assessed the frequencies of female sex, allergy, and malignancy in patients with each affected organ (Table 1). The organs with high frequencies of women included the lachrymal gland (50%), lungs (44%), and submandibular gland (43%). Those with low frequencies of women included the thyroid gland (0%), retroperitoneum (17%), and para-aorta (19%). In addition, allergic diseases were found in 60 patients (36%) (<b>Fig. 1A</b>). The organs with high frequencies of allergy included the thyroid gland (50%), submandibular gland (47%), and lachrymal gland (40%). Those with low frequencies of allergy were the para-aorta (13%), prostate gland (30%), and retroperitoneum (31%). Malignancies were found in 23 (14%) patients (<b>Fig. 1B</b>). Organs with high frequencies of malignancy included the para-aorta (38%), prostate gland (30%), and retroperitoneum (21%). In comparison, those with low frequencies of malignancy included the thyroid gland (0%), lungs (8%), and kidney (8%). <h3>Conclusion</h3> Craniocervical organ involvement was associated with female sex and presence of allergic diseases, suggesting that allergy may contribute to onset of IgG4-RD in some patients. Abdominal organ involvement was associated with male sex and presence of malignancies, suggesting that malignancy may in part contribute to IgG4-RD. <h3>Reference</h3> [1] Wang, et al., Rheumatology, 2018. [2] Shirakashi, et al., Sci Rep, 2018. <h3>Disclosure of Interests</h3> Hajime Yoshifuji: None declared, Mirei Shirakashi: None declared, Yuzo Kodama: None declared, Tsutomu Chiba: None declared, Motohisa Yamamoto: None declared, Hiroki Takahashi: None declared, Kazushige Uchida: None declared, Kazuichi Okazaki: None declared, Tetsuya Ito: None declared, Shigeyuki Kawa: None declared, Kazunori Yamada: None declared, Mitsuhiro Kawano: None declared, Shintaro Hirata Grant/research support from: Eli Lilly, UCB, Consultant for: Bristol-Myers Squibb, Jansen, UCB, Paid instructor for: AbbVie, Eisai, Tanabe-Mitsubishi, Speakers bureau: AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, UCB, Yoshiya Tanaka Grant/research support from: Abbvie, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, MSD, Ono, Taisho-Toyama, Takeda, Speakers bureau: Abbvie, Asahi-kasei, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eli Lilly, Eisai, Glaxo-Smithkline, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer Japan Inc, Sanofi, Takeda, UCB, YL Biologics, Masafumi Moriyama: None declared, Seiji Nakamura: None declared, Terumi Kamisawa: None declared, Shoko Matsui: None declared, Hiroto Tsuboi: None declared, Takayuki Sumida Grant/research support from: Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb, Motoko Shibata: None declared, Hiroshi Goto: None declared, Yasuharu Sato: None declared, Tadashi Yoshino: None declared, Tsuneyo Mimori: None declared